Creatine uptake promotes dendritic cell activation and enhances antitumor immunity
-
Context & Motivation:
- Most cancer immunotherapies target cytotoxic CD8⁺ T cells, but overall response rates remain limited (typically 20%–40%).
- Effective T cell priming depends on dendritic cells (DCs), which capture tumor antigens and orchestrate antitumor immune responses.
-
Upregulation of Creatine Transport in Tumors:
- Dendritic cells infiltrating tumor microenvironments significantly upregulate the gene encoding the creatine transporter compared to DCs in healthy tissues.
- This indicates an increased cellular demand for creatine uptake under the metabolic stress of the tumor niche.
-
Consequences of Creatine Deficiency:
- Knockout of the creatine transporter in DCs led to decreased survival, reduced activation markers, and impaired antigen presentation.
- Creatine-deficient DCs exhibited a diminished capacity to stimulate T cell proliferation and antitumor cytokine production.
-
In Vivo Antitumor Effects:
- Daily creatine supplementation in mouse melanoma models significantly suppressed tumor growth.
- Supplementation increased the frequency and activation state of tumor-infiltrating DCs and enhanced chemokine secretion that recruits additional immune cells to the tumor.
-
Metabolic Mechanism:
- Creatine serves as an intracellular energy buffer, shuttling into the phosphocreatine system to increase intracellular ATP availability.
- Elevated ATP levels sustain critical inflammatory and signaling pathways necessary for DC activation, allowing them to remain functional despite nutrient competition in the tumor microenvironment.
-
Translational Relevance:
- Ex vivo treatment of human monocyte-derived DCs with creatine enhanced their activation and ability to stimulate human T cells against cancer targets.
- Findings highlight two prospective clinical applications: using creatine as an adjuvant to complement existing checkpoint immunotherapies, and incorporating it during the manufacturing of DC-based cancer vaccines.